© Reuters. FILE PHOTO: A vial of the Pfizer/BioNTech COVID-19 vaccine is seen at the Royal Victoria Hospital in Belfast
(Reuters) – Rating agency Moody’s (NYSE:) Investors Service said on Sunday that Pfizer Inc (NYSE:)’s U.S. COVID-19 vaccine authorization is credit positive.
“The approval is credit positive because of incremental profit and cash flow from sales of the vaccine,” Moody’s said https:// “The revenue and profit opportunities for Pfizer are significant because it has priced the vaccine at a profit.”
The Pfizer/BioNTech vaccine in a large clinical trial was 95% effective in preventing illness. U.S. regulators late on Friday authorized emergency use of the vaccine, following similar moves by the UK and Canada.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.